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Breast cancer biological subtypes and protein
expression predict for the preferential distant
metastasis sites: a nationwide cohort study
Harri Sihto1,2*, Johan Lundin3,4, Mikael Lundin3, Tiina Lehtimäki3, Ari Ristimäki5,6, Kaija Holli7, Liisa Sailas8,9,
Vesa Kataja9,10, Taina Turpeenniemi-Hujanen11, Jorma Isola12, Päivi Heikkilä5 and Heikki Joensuu1,2
Abstract
Introduction: Some molecular subtypes of breast cancer have preferential sites of distant relapse. The protein
expression pattern of the primary tumor may influence the first distant metastasis site.
Methods: We identified from the files of the Finnish Cancer Registry patients diagnosed with breast cancer in five
geographical regions Finland in 1991-1992, reviewed the hospital case records, and collected primary tumor tissue.
Out of the 2,032 cases identified, 234 developed distant metastases after a median follow-up time of 2.7 years and
had the first metastatic site documented (a total of 321 sites). Primary tumor microarray (TMA) cores were analyzed
for 17 proteins using immunohistochemistry and for erbB2 using chromogenic in situ hybridization, and their
associations with the first metastasis site were examined. The cancers were classified into luminal A, luminal B,
HER2+ enriched, basal-like or non-expressor subtypes.
Results: A total of 3,886 TMA cores were analyzed. Luminal A cancers had a propensity to give rise first to bone
metastases, HER2-enriched cancers to liver and lung metastases, and basal type cancers to liver and brain
metastases. Primary tumors that gave first rise to bone metastases expressed frequently estrogen receptor (ER) and
SNAI1 (SNAIL) and rarely COX2 and HER2, tumors with first metastases in the liver expressed infrequently SNAI1,
those with lung metastases expressed frequently the epidermal growth factor receptor (EGFR), cytokeratin-5 (CK5)
and HER2, and infrequently progesterone receptor (PgR), tumors with early skin metastases expressed infrequently
E-cadherin, and breast tumors with first metastases in the brain expressed nestin, prominin-1 and CK5 and
infrequently ER and PgR.
Conclusions: Breast tumor biological subtypes have a tendency to give rise to first distant metastases at certain
body sites. Several primary tumor proteins were associated with homing of breast cancer cells.
Introduction
Breast cancer is the most common cancer in women
worldwide with approximately 1.15 million new cases
diagnosed annually [1]. Although the prognosis of breast
cancer patients is generally favorable and mortality has
declined due to early detection and improved adjuvant
therapies [2], distant metastases are not uncommon and
women with advanced disease still have a median survi-
val time of only approximately two years [3,4]. Bone,
liver, lung and soft tissue metastases are common, but
breast cancer can give rise to metastases at almost any
site. The site of distant metastasis is associated with the
length of survival; patients with brain metastases or
metastases at multiple sites generally have the least
favorable outcomes [4].
Besides host factors, the propensity of breast cancer to
give rise to distant metastases depends on the molecular
type of breast cancer, and the gene expression profile of
the primary tumor may predict the risk of distant recur-
rence [5,6]. Breast cancers are often divided into five
molecular subtypes based on their gene expression pro-
files (the luminal A, luminal B, HER2-enriched, basal-
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like, and the normal-like subtypes). These subtypes have
preferential sites for distant relapse [7,8], and the sub-
type may also be associated with efficacy of systemic
cancer therapies [9,10].
The gene array-based breast cancer molecular sub-
types have been approximated using a panel of five sur-
rogate markers (estrogen receptor (ER), progesterone
receptor (PgR), human epidermal growth factor recep-
tor-2 (HER2), epidermal growth factor receptor (EGFR),
and cytokeratin-5 (CK5)) as assessed by immunohisto-
chemistry [11]. Such immunohistochemistry-based sub-
types have roughly similar clinical characteristics and
behavior as the respective subtypes defined by gene
expression arrays [11], and they also predict for the sites
of distant metastases [12].
Several studies have addressed the relations between
the primary breast tumor protein or mRNA expression
profiles and the site of distant metastases [8,12-15], but
these reports have rarely differentiated between the first
and the later metastatic sites. During breast cancer pro-
gression distant metastases are found at an increasing
number of different body sites [16], and due to cancer
heterogeneity the associations between the primary
tumor properties and the metastasis predilection sites
may be increasingly confounded as cancer progresses.
Therefore, in the present study we made an attempt to
investigate the associations between the primary tumor
protein expression, as assessed by immunohistochemis-
try, and the first site of cancer distant recurrence. We
correlated the first distant metastatic site with 18
selected primary tumor molecular features that are
linked with the breast cancer molecular subtype, epithe-
lial-mesenchymal transition, myoepithelial or stem cell-
like features, or are a potential drug target. To reduce
the risk of a selection bias, the study is based on a
nationwide cohort of breast cancer patients. The results
suggest that the primary tumor protein expression pat-
tern is often predictive for the first site of distant
metastases.
Materials and methods
Patients
Women diagnosed with breast cancer and who lived
within one of five well-defined geographical areas in
Finland in 1991 or 1992 were identified from the files of
the Finnish Cancer Registry [17]. This cohort includes
2,930 breast cancer patients comprising 53% of all breast
cancers diagnosed in Finland in 1991 and 1992 (n =
5,551). Clinical data were extracted from the hospital
case records and survival data were obtained also from
the files of the Finnish Cancer Registry and the Statistics
Finland.
In each case an attempt to collect data on 50 charac-
teristics was made. The minimum data for inclusion in
the current study consisted of the date of the diagnosis,
age at diagnosis, postsurgical Tumor-Node-Metastasis
classification, availability of follow-up data after breast
surgery and the vital status data at the end of follow up.
We excluded from the study women who had distant
metastases at the time of the diagnosis, bilateral breast
cancer or other malignancy than breast cancer in history
except basal cell carcinoma of the skin, cervical carci-
noma in situ, or ductal or lobular breast carcinoma in
situ. A total of 2,032 patients fulfilled these inclusion
criteria (Figure 1). We next excluded patients whose
breast tumor subtype classification could not be done
because of missing information regarding expression of
EGFR, HER2, ER, PgR, or CK5, or whose cancer did not
give rise to distant metastases during the follow up (n =
1,694). In 104 cases of the remaining 338 patients with
distant breast cancer recurrence, the first site of distant
metastasis was not available leaving 234 (11.5%) of the
2,032 patients in the final study cohort. Of these 234
patients with a recorded first site of distant relapse, 165
(70.5%) were diagnosed with distant metastases at only
one body site (considering the skeleton, the lungs and
the subcutaneous tissue as one site), and 69 (29.5%)
patients had first metastases at more than one site
(median, 2.3 sites). The total number of the first meta-
static sites in these 234 patients was 321.
A total of 137 (58.5%) of the 234 patients were treated
with systemic adjuvant therapy after breast surgery.
Adjuvant therapy consisted of tamoxifen in 53 cases,
toremifene in 14, other hormonal therapy in three, CMF
(cyclophosphamide, methotrexate, fluorouracil) in 56,
and CEF (cyclophosphamide, epirubicin, fluorouracil) of
CAF (cyclophosphamide, doxorubicin, fluorouracil) in
five; in six cases the type of systemic adjuvant therapy
given was not available.
The median follow-up time of the 234 subjects
included in study was 9.3 years after the diagnosis to
the date of death, and the median time to first detection
of distant metastases from the date of breast cancer
diagnosis was 2.7 years (range, from 0.1 to 9.6 years).
The patients were usually followed up at hospital out-
patient departments or at health centers according to
the institutional practice. Besides bi-annual mammogra-
phy, imaging examinations were usually not carried out
in asymptomatic patients. Presence of metastatic breast
cancer was confirmed histologically, cytologically, or by
radiological imaging. The staging examinations at the
time of detection of distant metastases typically involved
an isotope bone scan and computed tomography of the
trunk.
Tumor tissue microarray and molecular subtypes
Permission to collect data from registries, files, and hos-
pital records and to use formalin-fixed paraffin-
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embedded tissues for research purposes was provided by
the Ministry of Social Affairs and Health, Finland (per-
mission 123/08/97). Representative tumor regions were
identified from H&E-stained formalin-fixed paraffin-
embedded tissue sections, following which tissue micro-
array (TMA) blocks were constructed using a 0.6 mm
diameter punch needle [18]. Sections of 5 μm were cut
and processed for immunohistochemistry.
The cancers were classified into five biological sub-
types; luminal A (ER+ and/or PgR+, HER2-), luminal B
(ER+ and/or PgR+, HER2+), basal-like (ER-, PgR-,
HER2-, CK5+ and/or EGFR+), HER2-enriched (HER2+,
ER-, PgR-), and non-expressor type (negative for all five
key classifiers). The non-expressor type corresponds to
unclassifiable triple-negative breast cancer [19].
Immunohistochemistry
Immunostainings for ER, PgR, HER2, EGFR, CK5, CK18,
Ki-67, p53, GATA3, COX2, smooth muscle actin
(SMA), and KIT were carried out using the antibodies
and dilutions provided in Table 1. Immunostaining and
evaluation of protein expression were carried out as
described in detail elsewhere [18,20-22]. In brief, ER,
PgR, CK5, CK18, Ki-67, p53, GATA3, and SMA expres-
sion were classified based on the percentage of positive
tumor cells out of all tumor cells in the sample. Expres-
sion was considered negative when less than 10% of
tumor cell nuclei expressed protein, except for Ki-67
and p53, where we used a cut-off of 20% [18,23]. Immu-
nostainings for EGFR and KIT were classified based on
the staining intensity accounting both for membranous
and cytoplasmic staining rather than the percentage of
staining cancer cells due to the uniform staining pattern
of tumor, and using a scale negative (-), low (+), inter-
mediate (++), or high (+++) [11,21]. Immunostaining for
COX2 was considered positive when moderate to strong
cytoplasmic staining was present in more than 10% of
tumor cells, and immunostaining for HER2 was consid-
ered positive when strong intensity of membranous
staining was present in the majority (> 50%) of cancer
cells [18,22,24].
To assess expression of SNAI1 (SNAIL), SNAI2
(SLUG), E-cadherin, prominin-1 (CD133/1) and nestin,
the tissue sections were deparaffinized and rehydrated,
and prior to immunostainings antigen retrieval was car-
ried out in sodium citrate buffer (pH 6.0, 10 mmol/L)
2,032 women with unilateral, invasive, operable early breast cancer 
diagnosed within a defined geographical region in Finland in 1991 or 1992; 
minimum clinical data available; no other malignancy in history
965 had no distant 
cancer recurrence
Site of the first distant 
metastases unknown, n=104
Site of the first distant 
metastases known n=234
- One site, n=165
- Multiple sites n=69
338 had distant metastases diagnosed
in 1991-2001
729 had biological 
subtype classification 
not available
Excluded
Excluded
Excluded
Figure 1 Patient inclusion in the study.
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by heating the samples in an autoclave at 120°C for two
minutes except for immunostaining for nestin, where no
antigen retrieval was used. The immunostainings were
performed following the manufacturer’s protocol using
the antibodies provided in Table 1 and a PowerVision+
Poly-HRP-histostaining kit (DVPB+110DAP, Technolo-
gies Co, Daly City, CA, USA) or a Vectastain-Elite goat
kit (Vector Laboratories, Inc, Burlingame, CA, USA) to
detect SLUG expression. The immunostainings were
first graded as either negative (-), low expression (+, ≤
10% of cells or nuclei positive), moderate expression (+
+, 11 to 50% positive), or high expression (+++, > 50%
positive), but in further analysis expression was grouped
as either negative (-) or positive (+, ++, or +++).
Chromogenic in situ hybridization
The HER2 gene copy numbers were determined using
chromogenic in situ hybridization (CISH) [18]. HER2
amplification was considered to be present when six or
more signals were detected per nucleus in more than
50% of cancer cells or when signal clusters were seen.
Statistical analyses
Frequency tables were analyzed using the chi squared
test or Fisher’s exact test. All P values are two-tailed.
Results
Cancer molecular subtype and the first site of distant
metastases
A total of 3,886 representative tumor tissue samples
were analyzed using immunohistochemistry with 17 dif-
ferent antibodies or with CISH. The most common first
sites of distant metastases were the bone (39.6%), the
liver (17.8%), and the lung (13.1%, Table 2).
Women with luminal A cancer had the first metastatic
site in the bone more often compared with women with
breast cancer of some other subtype (in 77 (47.0%) of
164 vs. 50 (31.8%) of 157 first distant sites the site was
in the bone, P = 0.006, Table 2). HER2-positive and ER-
and PgR-negative cancers tended to give rise first to
liver metastases more frequently compared with the
other subtypes (in 13 (27.1%) of 48 vs. 44 (16.1%) of 273
first distant sites the site was in the liver, P = 0.067).
Compared with the other biological subtypes, luminal A
cancers rarely gave rise to lung metastases first (in 14
(8.5%) of 164 cases vs. 28 (17.8%) of 157 cases the first
distant site was the lung, respectively, P = 0.014). Brain
metastases were rarely the first metastatic site (3.4%),
and brain metastases occurred more frequently in
women who had either the basal type or the non-
expressor type as compared with the rest of the sub-
types (in 4 (9.5%) of 42 vs. 7 (2.5%) of 279 sites, P =
0.043; and in 3 (12.5%) of 24 vs. 8 (2.8%) out of 297
sites, P = 0.04, respectively). First metastases manifested
rarely in the ovary or in the peritoneum (n = 9); this
occurred only in women diagnosed with hormone
receptor (HR)-positive cancer.
Women with the basal type of breast cancer had
more often the first distant metastases at multiple sites
compared with women with other subtypes of breast
cancer (13 (50.0%) of 26 vs. 56 (26.9%) of 208, P =
0.015; Figure 2).
Tumor protein expression and the first site of distant
metastases
Expression of several of the 17 single proteins analyzed
from the breast tumor was associated with the first site
of cancer distant recurrence. The associations between
expression of eight breast tumor proteins and the first
distant metastasis sites are provided in Figure 3.
Women whose breast cancer expressed EGFR, in parti-
cular, had frequently more than one metastatic site at
the time when the first distant metastases were detected.
Bone metastases were often the first distant metastasis
site when the tumor expressed SNAI1 or ER (87 (60.0%)
of the 145 patients with SNAI1-positive tumor were first
diagnosed with bone metastases as compared with 29
(42.0%) of the 69 women with SNAI1-negative tumor, P
= 0.014; similarly, 85 (59.9%) of the 142 women with
Table 1 Antibodies and their dilutions used in
immunohistochemistry
Target Clone Dilution Manufacturer
CK5 M7237 1:25 DakoCytomation, Glostrup, Denmark
CK18 NCL-CK18 1:20 Novocastra Laboratories Ltd, UK
COX2 160122 1:200 Cayman Chemical, Ann Arbor, MI, USA
E-
cadherin
#4065 1:200 Cell Signaling Technology Inc, Danvers,
MA, USA
EGFR NCL-EGFR 1:500 Novocastra Laboratories Ltd
ER 6F11 1:500 Novocastra Laboratories Ltd
GATA3 HG3-31 1:300 Santa Cruz Biotechnology Inc, Santa
Cruz, CA, USA
HER2 CB11 1:200 Novocastra Laboratories Ltd
Ki-67 MM-1 1:1000 Novocastra Laboratories Ltd
KIT A4502 1:300 DakoCytomation
Nestin MAB5326 1:400 Chemicon International Inc, Temecula,
CA, USA
p53 D07 1:500 Novocastra Laboratories Ltd
PgR 312 1:500 Novocastra Laboratories Ltd
Prominin AC133 1:10 Miltenyi Biotec GmbH, Germany
SMA M0581 1:100 DakoCytomation
SNAI1 ARP33314 1:400 Aviva Systems Biology, San Diego, CA,
USA
SNAI2 D-19 1:100 Santa Cruz Biotechnology Inc.
CK5, cytokeratin-5; CK18, cytokeratin 18; COX2, cyclooxygenase 2; EGFR,
epidermal growth factor receptor; ER, estrogen receptor; GATA3, GATA
binding protein 3; HER2, human epidermal growth factor receptor-2; PgR,
progesterone receptor; SMA, smooth muscle actin.
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Table 2 Breast cancer molecular subtype and the first site of distant metastases
First distant site of breast cancer
recurrence
Breast cancer
molecular subtype
No. of
patients1
No. of
metastatic sites
Bone Liver Lung Non-regional
lymph nodes
Skin Pleura Brain Other
n n n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Luminal A 123 164 77 (47.0) 29 (17.7) 14 (8.5) 10 (6.1) 12 (7.3) 9 (5.6) 3 (1.8) 10 (6.1)
Luminal B 30 43 15 (34.9) 5 (11.6) 7 (16.3) 5 (11.6) 5 (11.6) 3 (7.0) 0 (0.0) 3 (2.3)
HER2+/HR- 36 48 14 (29.2) 13 (27.1) 11 (22.9) 4 (8.3) 4 (8.3) 0 (0.0) 1 (2.1) 1 (2.1)
Basal-like 26 42 12 (28.6) 4 (9.5) 10 (20.8) 5 (11.9) 3 (7.1) 3 (7.1) 4 (9.5) 1 (2.4)
Non-expressor 19 24 9 (37.5) 6 (25.0) 0 (8.3) 2 (8.3) 0 (0.0) 3 (12.5) 3 (12.5) 1 (4.2)
Total 234 321 127 (39.6) 57 (17.8) 42 (13.1) 26 (8.1) 24 (7.5) 18 (5.6) 11 (3.4) 16 (5.0)
141, 13, 12, 16 and five patients with luminal A, luminal B, HER2+/HR-, basal-like, and non-expressor type of breast cancer, respectively, had more than one first
metastatic site. HER2, human epidermal growth factor receptor-2; HR, hormone receptor.
Figure 2 Associations between four biological subtypes of breast cancer and the first sites of distant metastases. The dark-shaded
(lower) parts of the columns depict the proportion of cancers that gave rise to more than one first metastatic site. The total number of
metastatic sites is provided in each panel. ER, estrogen receptor; HER2, human epidermal growth factor receptor-2.
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Figure 3 Association of eight breast tumor proteins with the first sites of distant metastases. The dark-shaded (lower) parts of the
columns depict the proportion of cancers that gave rise to more than one first metastatic site. The total number of metastatic sites is provided
in each panel. CK5, cytokeratin-5; COX2, cyclooxygenase 2; EGFR, epidermal growth factor receptor; ER, estrogen receptor; HER2, human
epidermal growth factor receptor-2; PgR, progesterone receptor.
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ER-positive cancer compared with 42 (46.7%) of the 90
women with ER-negative tumor had the first distant
metastases in the bone, P = 0.049, Table 3). On the
other hand, breast cancers that expressed COX2 were
infrequently associated with first distant metastases in
the skeleton (47 (43.5%) of the 108 COX2-positive can-
cers vs. 79 (63.7%) of the 124 COX2-negative cancers, P
= 0.002). Similarly, women with HER2-positive cancer
infrequently had bone as the first metastatic site com-
pared with those whose cancer was HER2-negative (29
(43.9%) of 66 vs. 98 (58.3%) of 168, respectively, P =
0.047).
Detection of the first distant recurrence in the liver was
associated with absence of SNAI1 expression in the
breast tumor. The liver was the first distant metastatic
site in 28 (19.3%) of the 145 women with SNAI1-positive
cancer as compared with 25 (36.2%) of the 69 patients
whose breast tumor did not express SNAI1 (P = 0.007).
Lung metastases as the first distant site were strongly
associated with breast tumor EGFR expression. Of the
36 women who had breast cancer expressing EGFR, 15
(41.7%) were first diagnosed with lung metastases as
compared with 20 (12.5%) of the 160 women whose
cancer was EGFR-negative (P < 0.0001). HER2-positive,
CK5-positive, p53-positive, and COX2-positive breast
cancers also often gave rise first to lung metastases (18
(27.3%) of 66 vs. 24 (14.3%) of 168, P = 0.020; 7 (33.3%)
of 21 vs. 29 (15.3%) of 189, P = 0.042; 15 (26.3%) of 57
vs. 25 (16.0%) of 156, P = 0.089; and 32 (29.6%) of 108
vs. 25 (20.2%) of 124, P = 0.095, respectively). Women
who had ER-positive, PgR-positive, or GATA3-positive
cancer were infrequently diagnosed first with lung
metastases (20 (14.1%) of 142 vs. 21 (23.3%) of 90, P =
0.072; 13 (12.3%) of 106 vs. 29 (23.4%) of 124, P =
0.030; and 21 (13.9%) of 151 vs. 16 (23.5%) of 68, P =
0.079, respectively).
Most breast cancers expressed E-cadherin in the series
(189 (89.6%) of the 211 evaluable cancers). Absence of
E-cadherin and SNAI2 expression in the breast tumor
tended to be associated with the first distant metastases
Table 3 Breast tumor protein expression and the first site of distant recurrence
First distant site of breast cancer recurrence
Protein No. of breast
cancers with
protein
expression/No.
of breast
cancers
examined
No. of first
metastatic sites
from cancers with
protein expression/
No. of all first
metastatic sitesa
Bone Liver Lung Skin Brain Other
n/Nb (%) n/N (%) n/Nc (%) n/Nc (%) n/Nc (%) n/Nc (%) n/Nc (%) n/Nc (%)
COX2 108/232 (46.6) 150/319 (47.0) 47/108 (43.5)*** 24/108 (22.2) 32/108 (29.6)* 11/108 (10.2) 7/108 (6.5) 29/108 (26.9)
HER2 66/234 (28.7) 91/321 (28.3) 29/66 (43.9)** 18/66 (27.3) 18/66 (27.3)** 9/66 (13.) 1/66 (1.5) 16/66 (24.2)
ER 142/232 (61.2) 192/317 (60.6) 85/142 (59.9)** 31/142 (21.8) 20/142 (14.1)* 17/142 (12.0) 3/142 (2.1)** 36/142 (25.4)
PgR 106/230 (46.1) 143/316 (45.3) 62/106 (58.5) 24/106 (22.6) 13/106 (12.3)** 11/106 (10.4) 1/106 (0.9)** 32/106 (30.2)
EGFR 36/196 (18.4) 64/269 (23.8) 16/36 (44.4) 11/36 (30.6) 15/36 (41.7)**** 6/36 (16.7) 3/36 (8.3) 13/36 (36.1)
CK5 21/207 (10.1) 30/285 (10.5) 9/21 (42.9) 3/21 (14.3) 7/21 (33.3)** 1/21 (4.8) 4/21 (19.0)** 6/21 (28.6)
Nestin 19/206 (9.2) 27/284 (9.5) 10/19 (52.6) 3/19 (15.8) 4/19 (21.1) 2/19 (10.5) 3/19 (15.8)* 5/19 (26.3)
Prominin-
1
15/180 (8.3) 23/246 (9.3) 6/15 (40.0) 3/15 (20.0) 4/15 (26.7) 1/15 (6.7) 3/15 (20.0)** 6/15 (40.0)
SMA 9/219 (4.1) 13/300 (4.3) 4/9 (44.4) 2/9 (22.2) 2/9 (22.2) 0/9 (0.0) 2/9 (22.2)* 3/9 (33.3)
SNAI1 145/214 (67.8) 200/296 (67.6) 87/145 (60.0)** 28/145 (19.3)*** 22/145 (15.2) 17/145 (11.7) 5/145 (3.4) 41/145 (28.3)
SNAI2 59/222 (26.6) 81/304 (26.6) 33/59 (55.9) 13/59 (22.0) 13/59 (22.0) 3/59 (5.1)* 3/59 (5.1) 16/59 (27.1)
CK18 215/222 (96.8) 294/303 (97.0) 114/215 (53.0) 53/215 (24.7) 39/215 (18.1) 22/215 (10.2) 10/215 (4.7) 56/215 (26.0)
E-
cadherin
189/211 (89.6) 259/288 (89.9) 104/189 (55.0) 46/189 (24.3) 34/189 (18.0) 16/189 (8.7)* 8/189 (4.2) 51/189 (27.0)
KIT 17/210 (8.1) 26/291 (8.9) 9/17 (52.9) 4/17 (23.5) 2/17 (11.8) 3/17 (17.6) 2/17 (11.8) 6/17 (35.3)
GATA3 151/219 (68.9) 209/302 (69.2) 88/151 (58.3) 38/151(25.2) 21/151 (13.9)* 16/151 (10.6) 5/151 (3.3) 41/151 (27.2)
Ki67 112/220 (50.9) 154/299 (51.5) 59/112 (52.7) 30/112(26.8) 24/112 (21.4) 9/112 (8.0) 5/112 (4.7) 27/112 (24.1)
p53 57/213 (26.8) 86/292 (29.5) 30/57 (52.6) 18/57 (31.6) 15/57 (26.3)* 5/57 (8.8) 3/57 (5.3) 15/57 (26.3)
aOne breast cancer may have given rise to more than one first metastatic sites.
bTwo to 54 tumors were not analyzed due to lack of tissue material.
cThe number of first metastatic sites from cancers with the protein expression/the number of breast cancers that expressed the protein.
*P < 0.10, **P < 0.05, ***P < 0.01, ****P < 0.001.
CK5, cytokeratin-5; CK18, cytokeratin 18; COX2, cyclooxygenase 2; EGFR, epidermal growth factor receptor; ER, estrogen receptor; GATA3, GATA binding protein 3;
HER2, human epidermal growth factor receptor-2; PgR, progesterone receptor; SMA, smooth muscle actin.
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in the skin (or the subcutaneous tissue). Only 16 (8.5%)
of the 189 women whose breast cancer expressed E-cad-
herin had the first distant metastases in the skin com-
pared with 5 (22.7%) of the 22 women whose cancer
was E-cadherin-negative (P = 0.051). Three (5.2%) of the
59 women whose breast cancer expressed SNAI2 had
the first distant cancer recurrence in the skin compared
with 21 (12.9%) of the 163 women whose cancer did not
express SNAI2 (P = 0.098). Many E-cadherin-negative
tumors had lobular morphology (11 (50.0%) of 22).
Brain metastases were rarely the first site of distant
recurrence. However, they were associated with expres-
sion of some of the proteins examined. Nestin, promi-
nin-1, CK5, and SMA was more often expressed in the
primary breast tumor when the first metastases were
found in the brain compared with other first metastatic
sites (3 (15.8%) of 19 vs. 7 (3.7%) of 187, P = 0.053; 3
(20.0%) of 15 vs. 6 (3.6%) of 165, P = 0.029; 4 (19.0%) of
21 vs. 7 (3.8%) of 186, P = 0.016; and 2 (22.2%) of 9 vs.
9 (4.3%) of 210, P = 0.068, respectively). Women who
had ER-positive or PgR-positive cancer rarely had the
brain as the first distant metastatic site compared with
women whose cancer did not express these proteins (3
(2.1%) of 142 vs. 8 (8.9%) of 90, P = 0.025; 1 (0.9%) of
106 vs. 10 (8.1%) of 124, P = 0.012).
HER2 amplification and the first site of distant recurrence
Presence of HER2 amplification in CISH in the breast
tumor and tumor HER2 expression in immunohisto-
chemistry were closely associated; 141 (95.2%) of the
148 breast tumors that did not contain HER2 amplifica-
tion did not express HER2, whereas 57 (80.3%) of the
71 tumors with HER2 amplification expressed HER2
protein (P < 0.0001). In line with the results obtained
with immunohistochemistry, patients who had HER2
amplification in the breast tumor had more often the
first distant metastases detected in the lung as compared
with women whose cancer was HER2-negative (20
(28.2%) of 71 vs. 20 (13.5%) of 148, P = 0.010), whereas
HER2-amplified breast cancers seldom gave first rise to
bone metastases compared with HER2-negative cancers
(32 (45.1%) of 71 vs. 90 (60.8%) of 148, P = 0.028).
The first site of distant recurrence and presence of
common drug targets
Finally, we examined whether the site of the first distant
cancer recurrence could be used as a surrogate for pre-
dicting presence of common drug target proteins in the
primary tumor. We selected for this analysis those
tumors that had first given rise to metastases either in
the bone (n = 102), the liver (n = 48), or the lung (n =
33) and that could be studied for expression of the
potential therapeutic target proteins ER, PgR, HER2, and
EGFR (Table 4). Tumors that gave first rise to bone
metastases were frequently ER positive and/or PgR posi-
tive (67.6%) and rarely EGFR-positive (15.7%), whereas
breast cancers that gave first rise to lung metastases
often expressed HER2 (48.5%) and EGFR (45.5%), very
frequently expressed either HER2 or EGFR (75.8%), and
infrequently expressed PgR (27.3%). Breast cancers that
gave rise first to liver metastases frequently expressed
ER (52.1%), PgR (37.5%), or HER2 (33.3%).
Discussion
The present results suggest that the first sites of breast
cancer distant metastases reflect expression of the pri-
mary breast tumor proteins, and that different biological
subtypes of breast cancer have a propensity to give rise
to distant metastases at specific body sites. Breast cancer
is a heterogeneous disease, and, as expected, the associa-
tions detected were only partial. Yet, the current results
lend support to the hypothesis that the first site of dis-
tant metastasis may give valuable clues of the biology of
the disease and perhaps also for selection of therapy.
In agreement with some prior studies, we found that
ER-positive breast cancers had a propensity to give rise
to bone metastases and that HER2-positive cancers give
rise to bone metastases less frequently than ER-positive
tumors [12,13,24]. As a novel finding, we found that
SNAI1-positive cancers also tend to home into the
Table 4 Breast tumor ER, PgR, HER2 and EGFR expression and the bone, the liver and the lungs as the first sites of
distant recurrence
Primary tumor protein expression First distant site of breast cancer recurrence
Bone Liver Lung
N = 102 n (%) N = 48 n (%) N = 33 n (%)
ER + 64 (62.7) 25 (52.1) 15 (45.5)
PgR + 46 (45.1) 18 (37.5) 9 (27.3)
ER + and/or PgR + 69 (67.6) 26 (54.2) 15 (45.5)
HER2 + 26 (25.5) 16 (33.3) 16 (48.5)
EGFR + (HER1) 16 (15.7) 11 (22.9) 15 (45.5)
EGFR + and/or HER2 + 37 (36.3) 20 (41.7) 25 (75.8)
EGFR, epidermal growth factor receptor; ER, estrogen receptor, HER1, human epidermal growth factor receptor-1; HER2, human epidermal growth factor receptor-
2; PgR, progesterone receptor.
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bone, whereas COX2-positive cancers do not. SNAI1 is
a zinc finger transcriptional repressor of CDH1, which
encodes E-cadherin. Downregulation of E-cadherin acti-
vates the “epithelial-mesenchymal transition”, which is
crucial for the dissemination and invasion of cancer
cells, loss of epithelial differentiation and acquisition of
a mesenchymal phenotype [25], which might augment
breast cancer metastasis into the bone. Moderate to
strong (elevated) expression of COX-2 protein is
observed in approximately one third of early breast can-
cers, and COX-2 expression is associated with a large
tumor size, a high histological grade, a negative HR sta-
tus, a high cell proliferation rate, high p53 expression,
presence of HER-2 amplification, and unfavorable survi-
val [22]. In accordance with the present data, some
observational findings suggest that the use of COX-2
inhibitors could reduce the risk of bone metastases in
stage II and III breast cancer [26], but this hypothesis
awaits confirmation in clinical trials.
The strongest single association detected in the pre-
sent study was the one between the breast primary
tumor EGFR expression and lung metastases, and as
many as 75.8% of all those patients whose first distant
recurrence was in the lung had either EGFR-positive or
HER2-positive primary breast tumor (Table 4). Experi-
mental mouse models suggest that EGFR is important
for tumor cell motility and invasion, and HER2 for
tumor cell intravasation [27]. The EGFR ligand epiregu-
lin, COX2, and the matrix metalloproteinases 1 and 2
collectively facilitate tumor cell entry into the blood-
stream and the breaching of lung capillaries by circulat-
ing tumor cells to seed lung metastases [28]. In line
with these and the present findings, erlotinib, an orally
administered inhibitor of the EGFR, prevented develop-
ment of pulmonary metastases in a spontaneous pul-
monary metastasis breast cancer mouse model, where
expression of EGF and EGFR turned out to be strong in
pulmonary metastatic nodules compared with primary
breast cancer [29]. Hypothetically, clinical testing of
dual inhibitors of EGFR and HER2, such as lapatinib,
neratinib, and BIBW 2992 (afatinib), might thus be of
particular interest in the relatively small subset of breast
cancer patients whose disease first recurs in the lungs.
In keeping with other studies [16], brain metastases
were infrequent as the first site of distant recurrence in
the present series. Brain metastases have been found to
be associated with HR-negative and triple-negative (ER-,
PgR-, HER2-) breast cancers [8,12,14,15,24,30], EGFR
expression [15], low Bcl-2 [15], and breast cancer HER2
expression and presence of HER2 amplification
[12,16,31]. However, one large study examining patients
from the pre-trastuzumab era did not find breast tumor
HER2 expression to be associated with brain metastases
[15], and a recent study found a higher incidence of
brain metastases only in those breast cancer patients
with HER2-positive breast cancer who had been treated
with trastuzumab [32]. In autopsy series, central nervous
system (CNS) metastases can be detected in approxi-
mately 30% of patients who have died from breast can-
cer [33,34], and since trastuzumab penetrates poorly
into the CNS but controls effectively non-CNS disease,
this might lead to manifestation of brain metastases dur-
ing trastuzumab treatment in some patients. The
patients in the present series were treated before the
trastuzumab era.
Brain metastases as the first site of distant recurrence
were associated most frequently with the basal subtype
and primary tumor expression of nestin, prominin-1, or
CK-5, and, on the other hand, they were rare when the
breast tumor expressed ER or PgR. To our knowledge,
the association between breast primary tumor nestin
and prominin-1 expression and the first recurrence of
cancer in the brain has not been reported earlier. Nestin
is a type VI intermediate filament protein that is
expressed in nerve cells and is considered a marker for
neural stem cells [35], and prominin-1/CD133 is a
neural and hematopoietic stem cell marker [36]. In a
landmark study, CD133-positive cell subpopulation iso-
lated from human brain tumors exhibited stem cell
properties and turned out to be the brain tumor initiat-
ing cells in a mouse model [37]. The biological mechan-
isms associated with these proteins and breast cancer
brain metastases remain hypothetical, but breast cancer
cells that express CD133 or nestin might share features
of neural stem cells and might thus be particularly well
adapted to the brain microenvironment to initiate brain
metastases.
This retrospective study has a few limitations. We did
not have histological tissue available from the first dis-
tant metastases. It is now established that a biopsy from
a metastatic site may yield a different result regarding
the ER or the HER2 status compared with the primary
tumor in 5 to 30% of cases [38,39]. This likely reflects
both heterogeneity of the disease already in the primary
tumor [40] and cancer progression with time, although
the biological type of the primary tumor is largely main-
tained in distant metastases [34]. The concept of the
first site of distant metastasis is not well-defined,
because at autopsy breast cancer metastases can be
found in many organs [34], and likely more metastatic
sites are found at the time of detection of the first
metastases the closer the patient is examined. Classifica-
tion of the primary tumors into categories based on
protein expression in immunohistochemistry is some-
what subjective, and the optimal cut-offs selected are
still being discussed even for proteins such as ER [41].
The adjuvant systemic treatments administered to 58.5%
of the patients may have influenced the first site of
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distant metastases, but adjuvant treatment has been
considered mandatory in the management of high-risk
early breast cancer for a few decades. We made an
attempt to avoid a selection bias by using a nationwide
series as the basis of the study, but a relatively large
proportion of patients who developed distant metastases
had to be excluded due to absence of adequate tissue
material or data on the first metastatic site. Finally, due
to multiple proteins analyzed, many statistical analyses
were carried out, which increases the probability of
obtaining a significant association by chance. Due to
these limitations and confounders, the study results
need to be viewed with some caution, although several
of the findings are well in line with prior clinical studies
or with experimental data.
Conclusions
We conclude that breast cancer biological subtypes are
associated with the first site of distant recurrence, and
that many commonly assessed proteins are associated
with homing of breast cancer at distant sites. In line
with prior studies, we found that ER-positive breast can-
cers often home in the bone, but we report several
novel findings. Besides ER, bone metastases are fre-
quently associated with tumor SNAI1 expression. Breast
cancers that first give rise to lung metastases very often
express either EGFR or HER2, which suggests that such
cancers might be a potential target group for dual HER1
and HER2 inhibitors, such as lapatinib or neratinib.
Cancers that express the basal CK-5 or the cell stem-
ness-linked proteins prominin-1 or nestin are associated
with the brain as the first site of distant recurrence.
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